A Phase I, Single-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects After Oral Multiple Ascending Doses.
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2010
At a glance
- Drugs AZD 2066 (Primary)
- Indications Gastro-oesophageal reflux; Neuropathic pain
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Dec 2010 Actual end date changed from Dec 2008 to Nov 2008 as reported by ClinicalTrials.gov.
- 09 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Nov 2008 Status changed from recruiting to active, no longer recruiting.